Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2012 06:00 ET | Source: NeurogesX

Trading in NeurogesX Common Stock to Move From NASDAQ to OTCBB

SAN MATEO, Calif., June 29, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
June 19, 2012 08:00 ET | Source: NeurogesX

NeurogesX Receives Notice of Two U.S. Patent Allowances Covering NGX-1998

SAN MATEO, Calif., June 19, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
June 18, 2012 08:00 ET | Source: NeurogesX

NeurogesX Issued Japanese Patent for NGX-1998

SAN MATEO, Calif., June 18, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
May 03, 2012 16:05 ET | Source: NeurogesX

NeurogesX Reports First Quarter 2012 Results

Q1 2012 and Recent Highlights: Engaged JSB-Partners, a global life sciences advisor, to assist the Company in executing its business development objectives for NGX-1998 and...
April 27, 2012 09:00 ET | Source: NeurogesX

NeurogesX to Hold Conference Call to Discuss First Quarter 2012 Results

SAN MATEO, Calif., April 27, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
April 20, 2012 16:05 ET | Source: NeurogesX

NeurogesX Receives Determination Letter From NASDAQ

SAN MATEO, Calif., April 20, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
April 17, 2012 07:30 ET | Source: NeurogesX

NeurogesX Engages JSB-Partners to Execute Business Development Strategy

SAN MATEO, Calif., April 17, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
April 11, 2012 07:30 ET | Source: NeurogesX

NeurogesX Provides Update on NGX-1998 Clinical Program

SAN MATEO, Calif., April 11, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
March 08, 2012 07:30 ET | Source: NeurogesX

NeurogesX Reports Fourth Quarter and Year-End 2011 Results

Q4 2011 and Recent Highlights: Positive NGX-1998 Phase 2 clinical trial in postherpetic neuralgia (PHN) patients met all study objectives Qutenza Q4 revenue totaled $3.0 million, including...
February 29, 2012 08:30 ET | Source: NeurogesX

NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Full Year 2011 Results

SAN MATEO, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...